文献速递浆细胞疾病

Linvoseltamab与Teclistamab对不同BCMA突变结合表位差异

Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations.
PubMed 文献 · Blood Adv · 2026-01-01

在表达4种BCMA突变的细胞系中比较linvoseltamab与teclistamab的结合与功能活性。Linvoseltamab保留对R27P和S30del的结合与细胞毒活性,而teclistamab活性降低;两者对P34del均活性受损,对P33S均保留活性。

要点

  • Linvoseltamab对BCMA R27P和S30del突变保留结合与T细胞激活及细胞毒活性。
  • Teclistamab对R27P和S30del突变结合与功能活性降低。
  • 两种双抗对P34del均活性受损,对P33S均保留活性。

核心结论

  • Linvoseltamab可能比teclistamab更不易受R27P和S30del相关耐药机制影响,但临床相关性待确立。

研究设计与样本

  • 使用表达4种BCMA突变(R27P、S30del、P34del、P33S)的细胞系比较两种BCMA×CD3双特异性抗体的活性。

主要发现

  • Linvoseltamab对R27P和S30del保留结合、Jurkat-NFAT报告及原代T细胞激活和细胞毒活性,与野生型BCMA相当。
  • Teclistamab对R27P和S30del结合与功能活性降低。
  • 两者对P34del结合受损,Jurkat-NFAT报告、原代T细胞激活和细胞毒活性均减弱。
  • 两者对P33S均保留活性。
  • 冷冻电镜显示两种双抗结合取向不同,所选残基对linvoseltamab结合贡献较小。

临床怎么用

  • 对于teclistamab治疗后出现BCMA R27P或S30del突变的患者,linvoseltamab可能提供替代选择,但需临床验证。

局限性

  • 研究为体外细胞系实验,临床相关性尚未确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell maturation antigen (BCMA) is a well-established therapeutic target in multiple myeloma (MM). BCMA mutations have been identified among patients who relapsed after treatment with approved BCMA×CD3 bispecific antibodies (bsAbs; eg, teclistamab). BCMA mutations can impair bsAb binding and cytotoxic activity in vitro, suggesting an acquired resistance mechanism leading to clinical relapse. Linvoseltamab (human BCMA×CD3 bsAb) was recently approved for adults with heavily pretreated relapsed/refractory MM. Here, we compared the activity of linvoseltamab in the presence of cell lines expressing 4 BCMA mutations reported among patients treated with teclistamab: R27P, S30del, P34del (associated with resistance), and the germ line variant P33S (identified in a patient who relapsed but was not associated with resistance). Linvoseltamab retained binding to cells expressing BCMA R27P and S30del mutations and demonstrated robust Jurkat-nuclear factor of activated T cells (NFAT) reporter and primary T-cell activation, as well as targeted cytotoxicity against mutated BCMA that was comparable to wild-type BCMA. Conversely, teclistamab exhibited reduced binding and functional activity against these mutations. Both linvoseltamab and teclistamab showed impaired binding against P34del, consistent with diminished Jurkat-NFAT reporter, primary T-cell activation, and cytotoxicity. Both bsAbs retained activity against P33S. Cryogenic electron microscopy uncovered distinct binding orientations for linvoseltamab and teclistamab, consistent with the respective sensitivities to the studied BCMA mutations (ie, the selected residues contributed less to linvoseltamab binding than teclistamab binding, consistent with the broader activity of linvoseltamab across BCMA mutations). Although linvoseltamab may be less susceptible than teclistamab to resistance mechanisms involving R27P and S30del, the clinical relevance of our findings is to be established.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Sineshchekova O, Lee K, et al. Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations. Blood Adv. 2026. PMID: 42509021. doi:10.1182/bloodadvances.2026020381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。